Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease
Generate an AI Snapshot to get a quick, structured summary of this paper.
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Evidence is provided that in mild Alzheimer’s disease, rivastigmine enhances brain activation in the fusiform and frontal cortices, which is compatible with the concept of cholinergic circuitry.
Abstract
These findings link the previously observed increase in cognitive performance in Alzheimer's disease after treatment with a cholinesterase inhibitor to altered brain activation. Although the results cannot be generalised to the Alzheimer's disease population at large, they provide evidence that in mild Alzheimer's disease, rivastigmine enhances brain activation in the fusiform and frontal cortices. This is compatible with the concept of cholinergic circuitry.
